SAN FRANCISCO– Miroculus, Inc., a developer of revolutionary tools for personal lab automation, today announced the appointment of Mark Lewis as Executive Chairman. Mark has served as a Board Member at Miroculus since October of 2018.
“We are excited to announce Mark’s new role as Executive Chairman at Miroculus. In addition to his broader board role, Mark will also work closely with our executive team on the commercialization of the recently introduced Miro Canvas™ and the development of future generations of our microfluidics platforms,” said Alejandro Tocigl, CEO of Miroculus. “His extensive experience in developing and commercializing integrated instrument platforms and proven senior leadership capabilities at leading organizations such as Illumina and Becton Dickinson will help execute on our mission to advance science and improve lives faster, together.”
“I look forward to working alongside the talented, dedicated team at Miroculus as we continue to advance solutions that allow researchers and clinicians to deploy even the most complex next generation sequencing protocols in their laboratories,” said Mark Lewis, Executive Chairman of Miroculus. “This is a particularly exciting time at Miroculus with the recent introduction of the Miro Canvas, which is ideally suited for supporting long-read Next Generation Sequencing (NGS) platforms, rapid whole genome sequencing and hybrid capture applications, among others. Miroculus is continuing to innovate in the microfluidics area with menu expansions and more fundamental technology improvements which we expect to implement in future products. NGS is our primary focus, but we are actively exploring opportunities to apply our technologies to other workflows in the life sciences,” Lewis said.
Mark has over 45 years of experience in the life sciences industry, developing and commercializing platforms and technologies for genotyping, DNA sequencing, molecular biology and high content screening. He previously served as interim CEO at Swift Biosciences, an NGS library prep provider in 2017 and 2018, and as a board member from 2017 until the company’s acquisition by Danaher in 2021. Mark also held several senior management roles at Illumina including Senior Vice President of Product Development where he directed the development of the HiSeq™ and MiSeq™ next generation sequencing platforms. Mark is also a board member at AEENA Dx, Inc. a non-invasive cancer diagnostics company as well as an advisor to UC San Diego as a member of the Dean’s Leadership Council for Biological sciences.
